Reuters logo
BRIEF-Scynexis says complete results from two PHASE 2 studies of oral SCY-078
October 5, 2016 / 8:41 PM / a year ago

BRIEF-Scynexis says complete results from two PHASE 2 studies of oral SCY-078

Oct 5 (Reuters) - SCYNEXIS Inc

* Announces complete results from two Phase 2 Studies of oral SCY-078 in patients with Candida spp. infections and closing of a $15 million term loan

* Well-tolerated and active oral dose of SCY-078 identified for invasive candidiasis patients

* Study results confirm overall antifungal activity of oral SCY-078 in patients with candida infections Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below